Диссертация (1141198), страница 18
Текст из файла (страница 18)
Circulation. 2003;108(2):135-42;11912061)lamifiban: results of the Platelet Aggregation Receptor Antagonist DoseInvestigation and Reperfusion Gain in Myocardial Infarction(PARADIGM)trial. J Am Coll Cardiol. 1998;32:2003–10;62)Langer A, Goodman SG, Topol EJ, et al; LATE Study Investigators.Late assessment of thrombolytic efficacy (LATE) study: prognosis in patientswith non-Q wave myocardial infarction. J Am Coll Cardiol. 1996;27:1327–32;63)Larson DM1, Duval S, Sharkey SW. et al. Safety and efficacy of apharmaco-invasive reperfusion strategy in rural ST-elevation myocardialinfarction patients with expected delays due to long-distance transfers. EurHeart J. 2012 May;33(10):1232-40;64)Lettieri C, Savonitto S, De Servi S, et al.
Emergency percutaneouscoronary intervention in patients with ST-elevation myocardial infarctioncomplicated by out-of-hospital cardiac arrest: early and medium-term outcome.Am Heart J. 2009;157:569 –75.e1.65)Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAIguideline for percutaneous coronary intervention: a report of the AmericanCollege of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines and the Society for Cardiovascular Angiography andInterventions. Circulation. 2011;124:e574–e651;66)McNamara RL, Herrin J, Bradley EH, et al. Hospital improvement intime to reperfusion in patients with acute myocardial infarction, 1999 to 2002.J Am Coll Cardiol.
2006;47:45–51;67)Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel comparedwith clopidogrel in patients undergoing percutaneous coronary intervention forST-elevation myocardial infarction (TRITON-TIMI 38): double-blind,randomised controlled trial. Lancet. 2009;373:723–31;12012168)Morrison LJ, Verbeek PR, McDonald AC, et al.
Mortality andprehospitalthrombolysisforacutemyocardialinfarction:ameta-analysis.JAMA. 2000;283:2686 –92;69)Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time savedby prehospital initiation of reteplase for ST-elevation myocardial infarction:results of The Early Retavase-Thrombolysis in Myocardial Infarction (ERTIMI) 19 trial. J Am Coll Cardiol. 2002;40:71–7;70)Motivala A., Cannon C., Srinivas V. et al.
Changes in myocardialinfarction guideline adherence as a function of patient risk. An end toparadoxal care? JACC 2011;57:1760—1765;71)Ohman EM, Kleiman NS, Gacioch G, et al. Combined acceleratedtissue-plasminogen activator and plateletglycoprotein IIb/IIIa integrin receptorblockade with Integrilin in acute myocardial infarction: results of arandomized, placebo-controlled, dose-ranging trial. Circulation. 1997;95:846 –54;72)Optimizing reperfusion therapy in acute ST-elevation myocardialinfarction by a pharmaco-invasive treatment approach in a well-organizednetwork Kurt Huber 3rd Department of Internal Medicine, Cardiology andEmergencyMedicine,Vienna,AustriaEuropeanHeartJournaldoi:10.1093/eurheartj/ehr42;73)Paul W. Armstrong, M.D., Anthony H. Gershlick, M.D., PatrickGoldstein, M.D.
et al. Fibrinolysis or Primary PCI in ST-Segment ElevationMyocardial Infarction. N Engl J Med 2013; 368:1379-1387;74)Paul W. Armstrong, MD; Cynthia M. Westerhout, PhD; Robert C.Welsh, MD Duration of Symptoms Is the Key Modulator of the Choice ofReperfusionforST-ElevationMyocardialInfarctionCirculation.2009; 119: 1293-1303;12112275)Peter H. Nielsen*; Michael Maeng, MD, PhD*; Martin Busk et al.Primary Angioplasty Versus Fibrinolysis in Acute Myocardial Infarction LongTerm Follow-Up in the Danish Acute Myocardial Infarction 2 TrialCirculation.2010; 121: 1484-1491Published online before print March 22,2010;76)Peter R.
Sinnaeve, MD, PhD1 ; Paul W. Armstrong, MD2 ; Anthony H.Gershlick, MD3STEMI Patients Randomized to a Pharmaco-Invasive StrategyorPrimaryPCI:TheSTREAM1-YearMortalityFollow-Up.CIRCULATIONAHA.114.009570Published online before print August 26,2014;77)Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferringST-segment-elevation myocardial infarction patients for percutaneous coronaryintervention compared with administration of onsite fibrinolytic declines asdelays increase. Circulation. 2011;124:2512–21;78)Poloński L1, Gasior M, Gierlotka M.
et al. Polish Registry of AcuteCoronary Syndromes (PL-ACS). Characteristics, treatments and outcomes ofpatients with acute coronary syndromes in Poland.Kardiol Pol. 2007Aug;65(8):861-72; discussion 873-4;79)Reynolds JC, Callaway CW, El Khoudary SR, et al. Coronaryangiography predicts improved outcome following cardiac arrest: propensityadjusted analysis. J Intensive Care Med. 2009;24:179–86;80)Ronner E, van Domburg RT, van den Brand MJBM, et al.
Platelet GPIIb/IIIa receptor blockers for failed thrombolysis in acute myocardialinfarction, alone or as adjunct to other rescue therapies: single centreretrospective analysis of 548 consecutive patients with acute myocardialinfarction. Eur Heart J. 2002;23:1529 –37;12212381)Rossi P, Bolognese L.
Comparison of intravenous urokinase plus heparinversus heparin alone in acute myocardial infarction: Urochinasi per viaSistemica nell’Infarto Miocardico (USIM) Collaborative Group. Am J Cardiol.1991;68:585–92;82)R Warren J. Cantor, M.D., David Fitchett Routine Early Angioplastyafter Fibrinolysis for Acute Myocardial Infarction, N Engl J Med 2009;360:2705-2718 ;83)Ryan Т.J., 1997. Ryan Т., Bauman W. et al. Guidelines forpercutaneous transluminal coronary angioplasty.
A report from theAmerican College of Cardiology / American heart Association.- JACC1993; 22: 2033 -2051Davies MJ. The pathophysiology of acute coronarysyndromes. Heart 2000;83:361-6;84)Sabatine, M.S., Cannon C.P., Gibson etal. Addition of clopidogrel toaspirin and fibrinolytic therapy for myocardial infarction with ST-segmentelevation. N Engl J Med 2005; 352:1179-89;85)Shamir R. Mehta, MD, MSc⁎; Sanjit S. Jolly, MD, MSc⁎; John Cairns,MD†. Effects of Radial Versus Femoral Artery Access in Patients With AcuteCoronary Syndromes With or Without ST-Segment Elevation J Am CollCardiol. 2012;60(24):2490-2499;86)Sundeep Mishra and Sunil Verma.
Application of STREAM trial inmanagement of acute myocardial infarction in real world practice.IndianHeart J. 2013 Sep; 65(5): 629–630;87)Sutton AG, Campbell PG, Price DJ, et al. Failure of thrombolysis bystreptokinase: detection with a simple electrocardiographic method. Heart.2000;84:149–56;88)Sutton AGC, Campbell PG, Graham R, et al. A randomized trial ofrescue angioplasty versus a conservative approach for failed fibrinolysis in ST123124segmentelevationmyocardialinfarction:theMiddlesbroughEarlyRevascularization to Limit INfarction (MERLIN) trial.
J Am Coll Cardiol.2004;44:287–96;89)Terkelsen CJ, Lassen JF, Nørgaard BL, et al. Are we underestimating thefull potential of early thrombolytic treatment in patients with acute myocardialinfarction? Heart. 2003;89:483– 4;90)Terkelsen CJ, Sørensen JT, Maeng M, et al. System delay and mortalityamong patients with STEMI treated with primary percutaneous coronaryintervention. JAMA.
2010;304:763–71;91)Ting HH, Rihal CS, Gersh BJ et al. Regional systems of care to optimizetimeliness of reperfusion therapy for ST-elevation myocardial infarction: theMayo Clinic STEMI Protocol. Circulation 2012;116:729–736;92)Vineet Bhan, MD; Warren J. Cantor, MD et al. Efficacy of EarlyInvasive Management Post-fibrinolysis in Men versus Women With STelevation Myocardial Infarction Am Heart J. 2012;164(3):343-350;93)Vogt A, von Essen R, Tebbe U, et al.
Impact of early perfusion status ofthe infarct-related artery on short-term mortality after thrombolysis for acutemyocardial infarction: retrospective analysis of four German multicenterstudies. J Am Coll Cardiol. 1993;21:1391–5;94)Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vshospital-initiated thrombolytic therapy: the Myocardial Infarction Triage andIntervention Trial. JAMA.
1993;270:1211– 6;95)Westerhout C.M., Bonnefoy E., Welsh R.C., et al. The influence of timefrom symptom onset and reperfusion strategy on 1-year survival in STelevation myocardial infarction: A pooled analysis of an early fibrinolyticstrategy versus primary percutaneous coronary intervention from CAPTIM andWEST. Am Heart J. 2011; 161: 283–290 ;12412596)Widimský P1, Budesínský T, Vorác D et al. Long distance transport forprimary angioplasty vs immediate thrombolysis in acute myocardial infarction.Final results of the randomized national multicentre trial--PRAGUE-2.
EurHeart J. 2003 Jan;24(1):94-104;97)Wijns W, Kolh P, Danchin N, Di Mario C. et al. Guidelines onmyocardial revascularization: the Task Force on Myocardial Revascularizationof the European Society of Cardiology (ESC) and the European Associationfor Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501–2555;98)www.clinicaltrials.gov The ELDERLY-ACS 2 trial. ClinicalTrials.govIdentifier: NCT01777503 (accessed September 9th, 2014);99)Yan Zhang and Yong Huo†‡ Early reperfusion strategy for acutemyocardial infarction: a need for clinical implementation J Zhejiang UnivSciB. 2011 Aug; 12(8): 629–632;100)Yong Huo†. Current status and development of percutaneous coronaryintervention in China. Zhejiang Univ Sci B.
2011; 11(8): 631–633.125126Приложение 1. Список таблиц и иллюстраций.Таблица №1.1. Рекомендации по соблюдению временных интервалов приоказании помощи пациентам с ОКСспST. Стр. 15.Таблица 1.2. Рекомендации по проведению первичного ЧКВ. Стр. 22.Таблица 2.1.1. Характеристика пациентов по полу и возрасту.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
